| Identification | Back Directory | [Name]
3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID | [CAS]
67-30-1 | [Synonyms]
TETRAC
tetraiodothyroaceticacid
Levothyroxine EP Impurity D
3,3’,5,5’-tetraiodo-thyroaceticaci
3,5,3',5'-Tetraiodothyroacetic acid
3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID
acide3,5,3’,5’-tetraiodothyroacetique
4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenylacetic acid
3,5-DIIODO-4-(4-HYDROXY-3,5-DIIODOPHENOXY)PHENYLACETIC ACID
3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)-benzeneaceticaci
3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)benzeneaceticacid
(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-aceticaci
4-[4-HYDROXY-3,5-DIIODOPHENOXY]-3,5-DIIODOBENZENEACETIC ACID
[3,5-Diiodo-4-(3,5-diiodo-4-hydroxyphenoxy)phenyl]acetic acid
Benzeneacetic acid,4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-
2-[3,5-Diiodo-4-(4-hydroxy-3,5-diiodophenoxy)phenyl]acetic acid
4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodobenzeneacetic acid, Tetrac | [EINECS(EC#)]
200-649-1 | [Molecular Formula]
C14H8I4O4 | [MDL Number]
MFCD00055932 | [MOL File]
67-30-1.mol | [Molecular Weight]
747.83 |
| Chemical Properties | Back Directory | [Melting point ]
219-220 °C (decomp) | [Boiling point ]
544.8±50.0 °C(Predicted) | [density ]
2.727±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
acetone: soluble19.60 20.40mg/mL, clear, colorless (or faintly yellow to yellow) | [form ]
powder to crystal | [pka]
3.98±0.10(Predicted) | [color ]
White to Yellow to Green | [InChI]
InChI=1S/C14H8I4O4/c15-8-4-7(5-9(16)13(8)21)22-14-10(17)1-6(2-11(14)18)3-12(19)20/h1-2,4-5,21H,3H2,(H,19,20) | [InChIKey]
PPJYSSNKSXAVDB-UHFFFAOYSA-N | [SMILES]
C1(CC(O)=O)=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1 |
| Hazard Information | Back Directory | [Uses]
Thyroid hormone analogue | [Definition]
ChEBI: A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'. | [Biochem/physiol Actions]
Studies in rats have reported that Tetrac may regulate TSH secretion under in vivo conditions1. | [in vivo]
Tetrac (35 μg; p.o. for 40 days) inhibits tumor inoculation, growth and integrin expression in mice[4]. | Animal Model: | Wild-type male Balb/C mice aged 8 weeks are inoculated with 102B16F10 or B16LS9 cells[4] | | Dosage: | 35 μg per day | | Administration: | P.o. (added to the drinking water) daily for 40 days | | Result: | Delayed the onset of ocular melanoma.
Reduced the S-100 and integrin staining level in the B16F10 mice model.
|
|
| Safety Data | Back Directory | [Hazard Codes ]
T+ | [Risk Statements ]
28 | [Safety Statements ]
45 | [RIDADR ]
UN 2811 6.1/PG 1
| [WGK Germany ]
3
| [RTECS ]
CY1585800
| [HS Code ]
2916.39.7900 | [HazardClass ]
6.1 | [Storage Class]
6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials | [Hazard Classifications]
Acute Tox. 2 Oral |
|
| Company Name: |
SYNTHENTA PVT LTD
|
| Tel: |
+91-7416102217 +91-7416102217 |
| Website: |
www.synthenta.com |
|